Aesthetic Appeal Does Not Render Design Patent Invalid
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
AUTOMOTIVE BODY PARTS ASS'N v. FORD GLOBAL TECHNOLOGIES, LLC
Before Hughes, Schall, and Stoll. Appeal from the United States District Court for the Eastern District of Michigan.
Summary: Aesthetic appeal is not an invalidating form of functionality for design patents; patent exhaustion and repair doctrines apply equally to utility patents and design patents.
ABPA, an association of auto body part companies, filed a declaratory judgement action against Ford seeking to invalidate design patents covering vehicle hood and headlight designs. According to ABPA, consumers prefer replacement parts that restore the original appearance of the vehicle. ABPA argued that Ford’s design patents were invalid because aesthetic appeal rendered the designs functional. ABPA also argued that Ford’s design patents were unenforceable under the doctrines of exhaustion and repair, and could not bar sales of replacement auto body parts that look like Ford’s original patented parts. The district court denied ABPA’s motion for summary judgment and sua sponte entered summary judgement in favor of Ford.
The Federal Circuit affirmed. On invalidity, the Court reasoned that the statutory basis and economic value of design patents derives from aesthetic appeal. If aesthetic appeal were functional so as to invalidate a design patent, that would gut the principles underlying design patents. The Court declined to extend the concept of aesthetic functionality in trademark law to design patents. The Court also explained that the exhaustion and repair doctrines apply only to authorized sales of the components actually sold. The repair doctrine does not allow wholesale replacement of component parts that are themselves protected by patent. Also, exhaustion does not apply to the unauthorized replacement parts manufactured by third parties.
Editor: Paul Stewart
Written by: Bryan J. Johnson & Mark Kachner
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…